Durvalumab + FLOT chemotherapy
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Neoplasms
Conditions
Gastrointestinal Neoplasms, Esophagogastric Junction
Trial Timeline
Nov 17, 2020 → Sep 27, 2027
NCT ID
NCT04592913About Durvalumab + FLOT chemotherapy
Durvalumab + FLOT chemotherapy is a phase 3 stage product being developed by AstraZeneca for Gastrointestinal Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT04592913. Target conditions include Gastrointestinal Neoplasms, Esophagogastric Junction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04592913 | Phase 3 | Active |
Competing Products
20 competing products in Gastrointestinal Neoplasms